Japanese pharma company...ready to provide generics as expiring patient dates arrive...BD
Takeda's quest to expand in the U.S. market--and off-set expiring patents on big drugs--continues. The Japanese company announced today a $1 billion alliance with RNAi company Alnylam. The deal covers RNAi therapeutics in the fields of oncology and metabolic disease with the option to expand to additional therapeutic areas in the future. Alnylam gets $100 million in up-front and additional $50 million in near-term technology transfer payments.